<html>
<head><meta http-equiv=Content-Type content="text/html; charset=UTF-8">
<style type="text/css">
<!--
span.cls_003{font-family:Times,serif;font-size:16.0px;color:rgb(0,0,0);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_003{font-family:Times,serif;font-size:16.0px;color:rgb(0,0,0);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_004{font-family:Times,serif;font-size:12.1px;color:rgb(0,0,0);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_004{font-family:Times,serif;font-size:12.1px;color:rgb(0,0,0);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_005{font-family:Times,serif;font-size:12.1px;color:rgb(0,0,0);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_005{font-family:Times,serif;font-size:12.1px;color:rgb(0,0,0);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_008{font-family:Times,serif;font-size:12.1px;color:rgb(0,0,0);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_008{font-family:Times,serif;font-size:12.1px;color:rgb(0,0,0);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_009{font-family:Times,serif;font-size:14.1px;color:rgb(0,0,0);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_009{font-family:Times,serif;font-size:14.1px;color:rgb(0,0,0);font-weight:bold;font-style:normal;text-decoration: none}
-->
</style>
<script type="text/javascript" src="9f6fd68c-13f6-11eb-8b25-0cc47a792c0a_id_9f6fd68c-13f6-11eb-8b25-0cc47a792c0a_files/wz_jsgraphics.js"></script>
</head>
<body>
<div style="position:absolute;left:50%;margin-left:-297px;top:0px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="9f6fd68c-13f6-11eb-8b25-0cc47a792c0a_id_9f6fd68c-13f6-11eb-8b25-0cc47a792c0a_files/background1.jpg" width=595 height=841></div>
<div style="position:absolute;left:72.02px;top:141.42px" class="cls_003"><span class="cls_003">Gilead to acquire Immunomedics for $21bn</span></div>
<div style="position:absolute;left:72.02px;top:178.62px" class="cls_004"><span class="cls_004">By Peter Moravec (London Business School) 14/09/2020</span></div>
<div style="position:absolute;left:72.02px;top:210.42px" class="cls_005"><span class="cls_005">Overview of the deal</span></div>
<div style="position:absolute;left:72.02px;top:234.18px" class="cls_004"><span class="cls_004">Acquirer: Gilead Sciences Inc.</span></div>
<div style="position:absolute;left:72.02px;top:250.17px" class="cls_004"><span class="cls_004">Target: Immunomedics Inc.</span></div>
<div style="position:absolute;left:72.02px;top:266.01px" class="cls_004"><span class="cls_004">Estimated value: $21bn</span></div>
<div style="position:absolute;left:72.02px;top:281.85px" class="cls_004"><span class="cls_004">Announcement date:</span></div>
<div style="position:absolute;left:72.02px;top:297.69px" class="cls_004"><span class="cls_004">Acquirer Advisors: Lazard and Morgan Stanley</span></div>
<div style="position:absolute;left:72.02px;top:313.53px" class="cls_004"><span class="cls_004">Target Advisors: Centerview Partners and BofA Securities</span></div>
<div style="position:absolute;left:72.02px;top:345.33px" class="cls_004"><span class="cls_004">Gilead Sciences, the company, known for its Covid-19 treatment Remdesivir has decided to</span></div>
<div style="position:absolute;left:72.02px;top:361.17px" class="cls_004"><span class="cls_004">branch out further into cancer treatment by agreeing to acquire Immunomedics. The two</span></div>
<div style="position:absolute;left:72.02px;top:377.01px" class="cls_004"><span class="cls_004">companies were previously in talks about a potential partnership but agreed that the new drug</span></div>
<div style="position:absolute;left:72.02px;top:392.97px" class="cls_004"><span class="cls_004">developed by Immunomedics would produce better sales under one firm. The deal is</span></div>
<div style="position:absolute;left:72.02px;top:408.81px" class="cls_004"><span class="cls_004">supposed to help Gilead diversify into other treatments. As breast-cancer therapy is currently</span></div>
<div style="position:absolute;left:72.02px;top:424.67px" class="cls_004"><span class="cls_004">a field which is being heavily invested in, the purchase could help Gilead capture a sizeable</span></div>
<div style="position:absolute;left:72.02px;top:440.51px" class="cls_004"><span class="cls_004">portion of the market. The stock closed at $42.25 on Friday, Sept. 11 the day of the deal</span></div>
<div style="position:absolute;left:72.02px;top:456.47px" class="cls_004"><span class="cls_004">announcement and at that number, Gilead would have to pay a 108% premium at an agreed</span></div>
<div style="position:absolute;left:72.02px;top:472.31px" class="cls_004"><span class="cls_004">share price of  $88 which is not unusual for biotech deals as such but is uncommon for deals</span></div>
<div style="position:absolute;left:72.02px;top:488.15px" class="cls_004"><span class="cls_004">of this size. Since then, on Monday, Sept. 14 share price has more than doubled at an open of</span></div>
<div style="position:absolute;left:72.02px;top:503.99px" class="cls_004"><span class="cls_004">86.89.</span></div>
<div style="position:absolute;left:72.02px;top:535.79px" class="cls_008"><span class="cls_008">“This acquisition represents significant progress in Gilead’s work to build a strong and</span></div>
<div style="position:absolute;left:72.02px;top:551.63px" class="cls_008"><span class="cls_008">diverse oncology portfolio” - Daniel O’Day, Gilead CEO</span></div>
<div style="position:absolute;left:72.02px;top:583.43px" class="cls_005"><span class="cls_005">Company details: Gilead</span></div>
<div style="position:absolute;left:72.02px;top:615.14px" class="cls_004"><span class="cls_004">Gilead Sciences Inc. is an American biopharmaceutical company which engages in research,</span></div>
<div style="position:absolute;left:72.02px;top:630.98px" class="cls_004"><span class="cls_004">development and commercialisation of medicines. The company is best known for being a</span></div>
<div style="position:absolute;left:72.02px;top:646.82px" class="cls_004"><span class="cls_004">leader in developing HIV drugs such as Truvada Genvoya. In recent months Gilead has</span></div>
<div style="position:absolute;left:72.02px;top:662.78px" class="cls_004"><span class="cls_004">gained further recognition for its Remdesivir drug used in COVID-19 treatment.</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:851px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="9f6fd68c-13f6-11eb-8b25-0cc47a792c0a_id_9f6fd68c-13f6-11eb-8b25-0cc47a792c0a_files/background2.jpg" width=595 height=841></div>
<div style="position:absolute;left:72.02px;top:86.34px" class="cls_004"><span class="cls_004">- </span><span class="cls_005">Founded in</span><span class="cls_004"> 1987, </span><span class="cls_005">headquartered in</span><span class="cls_004"> Foster City, California, United States</span></div>
<div style="position:absolute;left:72.02px;top:102.18px" class="cls_004"><span class="cls_004">- </span><span class="cls_005">CEO: </span><span class="cls_004">Daniel O'Day</span></div>
<div style="position:absolute;left:72.02px;top:118.14px" class="cls_005"><span class="cls_005">- Number of employees:</span><span class="cls_004"> 11,800</span></div>
<div style="position:absolute;left:72.02px;top:133.98px" class="cls_004"><span class="cls_004">- </span><span class="cls_005">Market Cap:</span><span class="cls_004">  $84,8bn (as of 14/09/2020)</span></div>
<div style="position:absolute;left:72.02px;top:149.82px" class="cls_004"><span class="cls_004">- </span><span class="cls_005">EV:</span><span class="cls_004">  $85.14bn</span></div>
<div style="position:absolute;left:72.02px;top:165.66px" class="cls_004"><span class="cls_004">- </span><span class="cls_005">LTM Revenue:</span><span class="cls_004"> $ 22.17bn</span></div>
<div style="position:absolute;left:72.02px;top:181.62px" class="cls_004"><span class="cls_004">- </span><span class="cls_005">LTM EBITDA:</span><span class="cls_004">  $5.56bn</span></div>
<div style="position:absolute;left:72.02px;top:197.46px" class="cls_005"><span class="cls_005">- LTM EV/Revenue:</span><span class="cls_004"> x3.8</span></div>
<div style="position:absolute;left:72.02px;top:213.30px" class="cls_004"><span class="cls_004">- </span><span class="cls_005">LTM EV/EBITDA:</span><span class="cls_004">  x15.6</span></div>
<div style="position:absolute;left:72.02px;top:245.10px" class="cls_005"><span class="cls_005">Company details: </span><span class="cls_004">Immunomedics</span></div>
<div style="position:absolute;left:72.02px;top:276.81px" class="cls_004"><span class="cls_004">Immunomedics Inc. is a biopharmaceutical company focused on developing antibody-based</span></div>
<div style="position:absolute;left:72.02px;top:292.65px" class="cls_004"><span class="cls_004">products for the treatment of cancer. The company has an extensive list of clinical</span></div>
<div style="position:absolute;left:72.02px;top:308.61px" class="cls_004"><span class="cls_004">collaborations with companies such as AstraZeneca, MedImmune and Roche. Its recent</span></div>
<div style="position:absolute;left:72.02px;top:324.45px" class="cls_004"><span class="cls_004">Trodelvy triple-negative breast cancer (TNBC) drug was approved in April of 2020.</span></div>
<div style="position:absolute;left:72.02px;top:356.13px" class="cls_005"><span class="cls_005">- Founded in</span><span class="cls_004"> 1982, </span><span class="cls_005">headquartered in </span><span class="cls_004">Morris Plains, New Jersey, United States</span></div>
<div style="position:absolute;left:72.02px;top:372.09px" class="cls_004"><span class="cls_004">- </span><span class="cls_005">CEO: </span><span class="cls_004">currently none, being led by executive chairman Behzad Aghazadeh</span></div>
<div style="position:absolute;left:72.02px;top:387.93px" class="cls_005"><span class="cls_005">- Number of employees:</span><span class="cls_004"> ~360</span></div>
<div style="position:absolute;left:72.02px;top:403.77px" class="cls_004"><span class="cls_004">- </span><span class="cls_005">Market Cap:</span><span class="cls_004">  $19.6bn (as of 14/09/2020)</span></div>
<div style="position:absolute;left:72.02px;top:419.61px" class="cls_004"><span class="cls_004">- </span><span class="cls_005">EV:</span><span class="cls_004">  $9.02bn (pre stock surge)</span></div>
<div style="position:absolute;left:72.02px;top:435.47px" class="cls_004"><span class="cls_004">- </span><span class="cls_005">LTM Revenue:</span><span class="cls_004"> $ 20.37m</span></div>
<div style="position:absolute;left:72.02px;top:451.43px" class="cls_004"><span class="cls_004">- </span><span class="cls_005">LTM EBITDA:</span><span class="cls_004">  - $309m</span></div>
<div style="position:absolute;left:72.02px;top:467.27px" class="cls_005"><span class="cls_005">- LTM EV/Revenue:</span><span class="cls_004"> x442</span></div>
<div style="position:absolute;left:72.02px;top:483.11px" class="cls_004"><span class="cls_004">- </span><span class="cls_005">LTM EV/EBITDA:</span><span class="cls_004">  negative</span></div>
<div style="position:absolute;left:72.02px;top:514.79px" class="cls_009"><span class="cls_009">Projections and assumptions</span></div>
<div style="position:absolute;left:72.02px;top:549.23px" class="cls_005"><span class="cls_005">Short-term consequences</span></div>
<div style="position:absolute;left:72.02px;top:581.03px" class="cls_004"><span class="cls_004">This deal will dig severely into Gilead’s cash and short-term equivalents as the company has</span></div>
<div style="position:absolute;left:72.02px;top:596.87px" class="cls_004"><span class="cls_004">cash reserves of around $20bn and the deal will be structured as a $15bn cash deal with the</span></div>
<div style="position:absolute;left:72.02px;top:612.74px" class="cls_004"><span class="cls_004">remaining $6bn coming from newly issued debt. Financing the deal primarily through cash is,</span></div>
<div style="position:absolute;left:72.02px;top:628.58px" class="cls_004"><span class="cls_004">however, an opportunity for the company to use its resources without taking on additional</span></div>
<div style="position:absolute;left:72.02px;top:644.54px" class="cls_004"><span class="cls_004">interest expenses as the company already had $23bn in long term debt at the end of 2019.</span></div>
<div style="position:absolute;left:72.02px;top:676.22px" class="cls_004"><span class="cls_004">Since advances in the understanding of the disease have been made be, Trodelvy,</span></div>
<div style="position:absolute;left:72.02px;top:692.06px" class="cls_004"><span class="cls_004">Immunomedics breast cancer-drug has additionally shown success in the treatment of lung</span></div>
<div style="position:absolute;left:72.02px;top:708.02px" class="cls_004"><span class="cls_004">and other types of cancer. Experts forecast that this could bring in further annual revenues of</span></div>
<div style="position:absolute;left:72.02px;top:723.86px" class="cls_004"><span class="cls_004">$3 bn to $5bn. Since in the first half of 2020 88% of Gilead’s revenues came from its</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:1702px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="9f6fd68c-13f6-11eb-8b25-0cc47a792c0a_id_9f6fd68c-13f6-11eb-8b25-0cc47a792c0a_files/background3.jpg" width=595 height=841></div>
<div style="position:absolute;left:72.02px;top:70.50px" class="cls_004"><span class="cls_004">established HIV and Hepatitis C drug portfolio, this acquisition aims to use its current cash</span></div>
<div style="position:absolute;left:72.02px;top:86.34px" class="cls_004"><span class="cls_004">cows to pay for new sources of revenue.</span></div>
<div style="position:absolute;left:72.02px;top:118.14px" class="cls_004"><span class="cls_004">Due to the decline of Gilead’s decline in sales of its hepatitis C drug and emerging</span></div>
<div style="position:absolute;left:72.02px;top:133.98px" class="cls_004"><span class="cls_004">competition for its HIV franchise, the company is looking to diversify its portfolio towards</span></div>
<div style="position:absolute;left:72.02px;top:149.82px" class="cls_004"><span class="cls_004">alternative streams of revenue. So far, the deal has undoubtedly benefited Immunomedics’</span></div>
<div style="position:absolute;left:72.02px;top:165.66px" class="cls_004"><span class="cls_004">shareholders substantially. Additionally, there do not seem to be any concerns with regulators</span></div>
<div style="position:absolute;left:72.02px;top:181.62px" class="cls_004"><span class="cls_004">as the company is branching out into different treatment types rather than focusing on</span></div>
<div style="position:absolute;left:72.02px;top:197.46px" class="cls_004"><span class="cls_004">acquiring direct competitors.</span></div>
<div style="position:absolute;left:72.02px;top:229.14px" class="cls_005"><span class="cls_005">Long-term upsides</span></div>
<div style="position:absolute;left:72.02px;top:260.97px" class="cls_004"><span class="cls_004">From a long-term perspective, this deal sets the way for Gilead to become a leader in breast</span></div>
<div style="position:absolute;left:72.02px;top:276.81px" class="cls_004"><span class="cls_004">cancer medicine with the potential to widen this to several other types of the disease. This</span></div>
<div style="position:absolute;left:72.02px;top:292.65px" class="cls_004"><span class="cls_004">acquisition will strengthen the potential to break into new fields and diversify its portfolio of</span></div>
<div style="position:absolute;left:72.02px;top:308.61px" class="cls_004"><span class="cls_004">tumour treatment drugs away from its key revenue drivers that have been declining in sales.</span></div>
<div style="position:absolute;left:72.02px;top:340.29px" class="cls_004"><span class="cls_004">After taking over in 2019, Daniel O'Day, CEO of Gilead has demonstrated the company is</span></div>
<div style="position:absolute;left:72.02px;top:356.13px" class="cls_004"><span class="cls_004">eager to grow with numerous transactions such as the $5.1bn partnership with Galapagos</span></div>
<div style="position:absolute;left:72.02px;top:372.09px" class="cls_004"><span class="cls_004">taking part ownership of its R&D projects division. Following this, the company has also</span></div>
<div style="position:absolute;left:72.02px;top:387.93px" class="cls_004"><span class="cls_004">acquired cancer-drug developer FortySeven for $4.9bn in the same year.</span></div>
<div style="position:absolute;left:72.02px;top:419.61px" class="cls_004"><span class="cls_004">This newest acquisition demonstrates that the management team realises that it must branch</span></div>
<div style="position:absolute;left:72.02px;top:435.47px" class="cls_004"><span class="cls_004">out to survive in this competitive industry. According to the WHO, cancer is the second</span></div>
<div style="position:absolute;left:72.02px;top:451.43px" class="cls_004"><span class="cls_004">leading cause of death globally, with an estimated 9.6 million deaths in 2018. As previously</span></div>
<div style="position:absolute;left:72.02px;top:467.27px" class="cls_004"><span class="cls_004">mentioned, Immunomedics' drug Trodelvy has potential to cure other forms of cancer and if</span></div>
<div style="position:absolute;left:72.02px;top:483.11px" class="cls_004"><span class="cls_004">further research confirms additional cancer treatment applications sales could multiply. This</span></div>
<div style="position:absolute;left:72.02px;top:498.95px" class="cls_004"><span class="cls_004">would further explain Gilead paying a substantial premium for the acquisition.</span></div>
<div style="position:absolute;left:72.02px;top:530.75px" class="cls_004"><span class="cls_004">Gilead being an established company, will be able to further provide Immunomedics with an</span></div>
<div style="position:absolute;left:72.02px;top:546.59px" class="cls_004"><span class="cls_004">established infrastructure outside the US, in regions such as Europe or Japan. This network is</span></div>
<div style="position:absolute;left:72.02px;top:562.43px" class="cls_004"><span class="cls_004">especially relevant as Immunomedics aims to file for approvals for its drug in Europe in the</span></div>
<div style="position:absolute;left:72.02px;top:578.39px" class="cls_004"><span class="cls_004">first half of next year. Through its acquisitions, the company has created a substantial and</span></div>
<div style="position:absolute;left:72.02px;top:594.23px" class="cls_004"><span class="cls_004">diversified growth portfolio, which has been predicted to generate as much as $15bn in new</span></div>
<div style="position:absolute;left:72.02px;top:610.10px" class="cls_004"><span class="cls_004">sales by 2030.</span></div>
<div style="position:absolute;left:72.02px;top:641.90px" class="cls_008"><span class="cls_008">“Trodelvy is an approved, transformational medicine for a form of cancer that is particularly</span></div>
<div style="position:absolute;left:72.02px;top:657.74px" class="cls_008"><span class="cls_008">challenging to treat,” - Daniel O’Day, Gilead CEO</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:2553px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="9f6fd68c-13f6-11eb-8b25-0cc47a792c0a_id_9f6fd68c-13f6-11eb-8b25-0cc47a792c0a_files/background4.jpg" width=595 height=841></div>
<div style="position:absolute;left:72.02px;top:70.50px" class="cls_005"><span class="cls_005">Risks and uncertainties</span></div>
<div style="position:absolute;left:72.02px;top:102.18px" class="cls_004"><span class="cls_004">Gilead has seen a decline in sales since its peak in 2016, thus looking for ways to branch out</span></div>
<div style="position:absolute;left:72.02px;top:118.14px" class="cls_004"><span class="cls_004">into new fields. Nonetheless, the company has a history of unsuccessful acquisitions, since in</span></div>
<div style="position:absolute;left:72.02px;top:133.98px" class="cls_004"><span class="cls_004">2017 the company had to write down its $12bn purchase of Kite Pharma. Gilead is betting on</span></div>
<div style="position:absolute;left:72.02px;top:149.82px" class="cls_004"><span class="cls_004">Trodelvy’s success and expects sales to pass $750m by 2023. However, Astra Zeneca, in</span></div>
<div style="position:absolute;left:72.02px;top:165.66px" class="cls_004"><span class="cls_004">partnership with Daiichi Sankyo, is working on a direct competitor that could severely cut</span></div>
<div style="position:absolute;left:72.02px;top:181.62px" class="cls_004"><span class="cls_004">into Trodelvy’s sales, which is the key value driver behind the acquisition. Failing to leverage</span></div>
<div style="position:absolute;left:72.02px;top:197.46px" class="cls_004"><span class="cls_004">it in time would considerably reduce the return on the investment.</span></div>
<div style="position:absolute;left:72.02px;top:229.14px" class="cls_004"><span class="cls_004">The acquisition bears several upsides. Yet, it is common in the pharma industry, for a drug to</span></div>
<div style="position:absolute;left:72.02px;top:245.10px" class="cls_004"><span class="cls_004">be denied FDA approval and to become several billion-dollar write-offs. This has to be</span></div>
<div style="position:absolute;left:72.02px;top:260.97px" class="cls_004"><span class="cls_004">considered when assessing transactions within the sector as they may end up as tail events,</span></div>
<div style="position:absolute;left:72.02px;top:276.81px" class="cls_004"><span class="cls_004">both positive and negative. Being granted approval in the aforementioned regions will be</span></div>
<div style="position:absolute;left:72.02px;top:292.65px" class="cls_004"><span class="cls_004">vital when assessing the synergies created by this deal.</span></div>
<div style="position:absolute;left:72.02px;top:324.45px" class="cls_004"><span class="cls_004">Even though Immunomedics stock price has surged after the deal announcement, Gilead has</span></div>
<div style="position:absolute;left:72.02px;top:340.29px" class="cls_004"><span class="cls_004">had less of a surge with the increase being around 2%. This may be attributed to the fact that</span></div>
<div style="position:absolute;left:72.02px;top:356.13px" class="cls_004"><span class="cls_004">the company is paying a more than 100% premium for Immunomedics, which traded at</span></div>
<div style="position:absolute;left:72.02px;top:372.09px" class="cls_004"><span class="cls_004">around 12% of its current value at the beginning of April. According to a recent report,</span></div>
<div style="position:absolute;left:72.02px;top:387.93px" class="cls_004"><span class="cls_004">however, 48 hedge funds, the highest to date for the company included Immunomedics in</span></div>
<div style="position:absolute;left:72.02px;top:403.77px" class="cls_004"><span class="cls_004">their portfolio. Wall Street seems to be in agreement that the company has a bright future</span></div>
<div style="position:absolute;left:72.02px;top:419.61px" class="cls_004"><span class="cls_004">ahead.</span></div>
</div>

</body>
</html>
